They also reported that MiR-627-5p improves lipid and glucose metabolism, key pathological components of NAFLD, in L-O2 cells by targeting fat mass and obesity-related gene (FTO). The gene discussed is FTO; the disease is metabolic dysfunction-associated steatotic liver disease.